JMB

Cited by CrossRef (20)

  1. Kaiyuan Deng, Hao Wang, Ting Shan, Yigang Chen, Hong Zhou, Qin Zhao, Jiazeng Xia. Tristetraprolin inhibits gastric cancer progression through suppression of IL-33. Sci Rep 2016;6
    https://doi.org/10.1038/srep24505
  2. Robert J. Rounbehler, Anders E. Berglund, Travis Gerke, Mandeep M. Takhar, Shivanshu Awasthi, Weimin Li, Elai Davicioni, Nicholas G. Erho, Ashley E. Ross, Edward M. Schaeffer, Eric A. Klein, R. Jeffrey Karnes, Robert B. Jenkins, John L. Cleveland, Jong Y. Park, Kosj Yamoah. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2018;27:1376
    https://doi.org/10.1158/1055-9965.EPI-18-0369
  3. JUN PAN, XIAOYONG ZHAO, CHUNNAN LIN, HONGCHAO XU, ZHILIN YIN, TIANZHU LIU, SHIZHONG ZHANG. Immune responsive gene 1, a novel oncogene, increases the growth and tumorigenicity of glioma. 2014;32:1957
    https://doi.org/10.3892/or.2014.3474
  4. Se-Ra Lee, Hua Jin, Won-Tae Kim, Won-Jung Kim, Sung Zoo Kim, Sun-Hee Leem, Soo Mi Kim. Tristetraprolin activation by resveratrol inhibits the proliferation and metastasis of colorectal cancer cells. Int J Oncol 2018
    https://doi.org/10.3892/ijo.2018.4453
  5. Yogesh Saini, Jian Chen, Sonika Patial. The Tristetraprolin Family of RNA-Binding Proteins in Cancer: Progress and Future Prospects. Cancers 2020;12:1539
    https://doi.org/10.3390/cancers12061539
  6. Heping Cao, Kandan Sethumadhavan, Fangping Cao, Thomas T. Y. Wang. Gossypol decreased cell viability and down-regulated the expression of a number of genes in human colon cancer cells. Sci Rep 2021;11
    https://doi.org/10.1038/s41598-021-84970-8
  7. Edward Hitti, Tala Bakheet, Norah Al-Souhibani, Walid Moghrabi, Suhad Al-Yahya, Maha Al-Ghamdi, Maher Al-Saif, Mohamed M. Shoukri, András Lánczky, Renaud Grépin, Balázs Győrffy, Gilles Pagès, Khalid S.A. Khabar. Systematic Analysis of AU-Rich Element Expression in Cancer Reveals Common Functional Clusters Regulated by Key RNA-Binding Proteins. Cancer Res 2016;76:4068
    https://doi.org/10.1158/0008-5472.CAN-15-3110
  8. Felicitas Rataj, Séverine Planel, Josiane Denis, Caroline Roelants, Odile Filhol, Laurent Guyon, Jean-Jacques Feige, Nadia Cherradi. Targeting AU-rich element-mediated mRNA decay with a truncated active form of the zinc-finger protein TIS11b/BRF1 impairs major hallmarks of mammary tumorigenesis. Oncogene 2019;38:5174
    https://doi.org/10.1038/s41388-019-0784-8
  9. Jeong-Min Park, Tae-Hee Lee, Tae-Hong Kang. Roles of Tristetraprolin in Tumorigenesis. IJMS 2018;19:3384
    https://doi.org/10.3390/ijms19113384
  10. Qamraa H. Al‐Qahtani, Walid N. Moghrabi, Suhad Al‐Yahya, Latifa Al‐Haj, Maher Al‐Saif, Linah Mahmoud, Falah Al‐Mohanna, Norah Al‐Souhibani, Ayodele Alaiya, Edward Hitti, Khalid S. A. Khabar. Kinome inhibition reveals a role for polo‐like kinase 1 in targeting post‐transcriptional control in cancer. Mol Oncol 2021
    https://doi.org/10.1002/1878-0261.12897
  11. Khalid S. A. Khabar. Hallmarks of cancer and AU-rich elements. WIREs RNA 2017;8:e1368
    https://doi.org/10.1002/wrna.1368
  12. Jian Guo, Huiheng Qu, Ye Chen, Jiazeng Xia. The role of RNA-binding protein tristetraprolin in cancer and immunity. Med Oncol 2017;34
    https://doi.org/10.1007/s12032-017-1055-6
  13. Travis Gerke, Himisha Beltran, Xiaodong Wang, Gwo-Shu Mary Lee, Andrea Sboner, R. Jeffrey Karnes, Eric A. Klein, Elai Davicioni, Kasra Yousefi, Ashley E. Ross, Daniela Börnigen, Curtis Huttenhower, Lorelei A. Mucci, Bruce J. Trock, Christopher J. Sweeney. Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:584
    https://doi.org/10.1158/1055-9965.EPI-18-0667
  14. Tarek Kröhler, Sonja M. Kessler, Kevan Hosseini, Markus List, Ahmad Barghash, Sonika Patial, Stephan Laggai, Katja Gemperlein, Johannes Haybaeck, Rolf Müller, Volkhard Helms, Marcel H. Schulz, Jessica Hoppstädter, Perry J. Blackshear, Alexandra K. Kiemer. The mRNA-binding Protein TTP/ZFP36 in Hepatocarcinogenesis and Hepatocellular Carcinoma. Cancers 2019;11:1754
    https://doi.org/10.3390/cancers11111754
  15. Se-Ra Lee, Jeong-Yeon Mun, Mi-So Jeong, Hyun-Hee Lee, Yun-Gil Roh, Won-Tae Kim, Min-Hye Kim, Jeonghoon Heo, Yung Hyun Choi, Su Jin Kim, Hee-Jae Cha, Mira Jun, Sun-Hee Leem. Thymoquinone-Induced Tristetraprolin Inhibits Tumor Growth and Metastasis through Destabilization of MUC4 mRNA. IJMS 2019;20:2614
    https://doi.org/10.3390/ijms20112614
  16. Li Xu, Huan Ning, Ling Gu, Qinghong Wang, Wenbao Lu, Hui Peng, Weiguang Cui, Baoling Ying, Christina R. Ross, Gerald M. Wilson, Lin Wei, William S.M. Wold, Jianguo Liu. Tristetraprolin induces cell cycle arrest in breast tumor cells through targeting AP-1/c-Jun and NF-κB pathway. Oncotarget 2015;6:41679
    https://doi.org/10.18632/oncotarget.6149
  17. Wen Jiang, Dandan Zhu, Chenghe Wang, Yu Zhu. Tumor suppressing effects of tristetraprolin and its small double‐stranded RNAs in bladder cancer. Cancer Med. 2021;10:269
    https://doi.org/10.1002/cam4.3622
  18. Tazeem Shaik, Gulam M. Rather, Nitu Bansal, Tamara Minko, Olga Garbuzenko, Zoltan Szekely, Emine E. Abali, Debabrata Banerjee, John E. Kerrigan, Kathleen W. Scotto, Joseph R. Bertino. Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer. Oncotarget 2018;9:33249
    https://doi.org/10.18632/oncotarget.26064
  19. Anders E. Berglund, Kristen E.N. Scott, Weimin Li, Chunying Yang, Mario R. Fernandez, Franz X. Schaub, John L. Cleveland, Robert J. Rounbehler. Tristetraprolin disables prostate cancer maintenance by impairing proliferation and metabolic function. Oncotarget 2016;7:83462
    https://doi.org/10.18632/oncotarget.13128
  20. Fei Dong, Cen Li, Pu Wang, Xiaoya Deng, Qinli Luo, Xiaokui Tang, Li Xu. The RNA binding protein tristetraprolin down-regulates autophagy in lung adenocarcinoma cells. Experimental Cell Research 2018;367:89
    https://doi.org/10.1016/j.yexcr.2018.03.028